Education
About Us
Working with TipRanks
Follow Us
Revelation Biosciences (REVB)
NASDAQ:REVB
Top Page
Revelation Biosciences
(NASDAQ:REVB)
Rating:28Underperform
Price Target:―
Revelation Biosciences (REVB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$819.23K
Dividend YieldN/A
Average Volume (3M)160.16K
Price to Earnings (P/E)―
Beta (1Y)0.31
Revenue GrowthN/A
EPS Growth-115.81%
CountryUS
Employees8
SectorHealthcare
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.11
Shares Outstanding963,796
10 Day Avg. Volume400,774
30 Day Avg. Volume160,165
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-0.08
Enterprise Value/Market Cap-2.25
Enterprise Value/Revenue-24.54
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$20.00Price Target Upside2252.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Revelation Biosciences Business Overview & Revenue Model
Company DescriptionRevelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
How the Company Makes MoneyRevelation Biosciences generates revenue primarily through the development and commercialization of its therapeutic candidates. The company's revenue model may include research and development collaborations, licensing agreements, and potential future product sales. Key revenue streams likely involve partnerships with larger pharmaceutical companies for joint development or commercialization efforts, as well as securing funding through grants or investments to support ongoing research. Currently, as a clinical-stage company, significant earnings may not be realized until products receive regulatory approval and reach the market.
Revelation Biosciences Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | 0.00 | -25.05K | -40.01K | -69.17K | 0.00 | EBIT |
| -8.17M | -7.98M | -8.66M | -10.86M | -11.95M | -145.49K | EBITDA |
| -8.14M | -7.95M | -95.21K | -10.84M | -11.93M | -145.49K | Net Income Common Stockholders |
| -14.41M | -15.04M | -120.25K | -10.79M | -11.99M | -1.63M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 14.55M | 6.50M | 11.99M | 5.25M | 1.27M | 4.49M | Total Assets |
| 14.70M | 6.62M | 12.21M | 5.50M | 2.04M | 4.62M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 16.75K | 0.00 | Net Debt |
| -14.55M | -6.50M | -11.99M | -5.25M | -1.26M | -4.49M | Total Liabilities |
| 5.23M | 1.91M | 5.56M | 4.45M | 2.14M | 1.21M | Stockholders Equity |
| 9.47M | 4.71B | 6.65M | 1.05M | -99.47K | 3.41M |
| Cash Flow | Free Cash Flow | ||||
| -23.28M | -18.34M | -7.29M | -11.22M | -11.22M | -215.07K | Operating Cash Flow |
| -23.24M | -18.32M | -7.29M | -11.22M | -11.09M | -215.07K | Investing Cash Flow |
| -301.14K | -19.17K | 0.00 | 0.00 | -131.96K | -74.04M | Financing Cash Flow |
| 12.85M | 12.85M | 14.03M | 15.20M | 8.00M | 74.26M |
Revelation Biosciences Technical Analysis
Negative
0.85
Price Trends
2.83
Negative
3.77
Negative
8.19
Negative
Market Momentum
-0.42
Positive
16.71
Positive
1.66
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REVB, the sentiment is Negative. The current price of 0.85 is below the 20-day moving average (MA) of 2.63, below the 50-day MA of 2.83, and below the 200-day MA of 8.19, indicating a bearish trend. The MACD of -0.42 indicates Positive momentum. The RSI at 16.71 is Positive, neither overbought nor oversold. The STOCH value of 1.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for REVB.
Revelation Biosciences Risk Analysis
Revelation Biosciences disclosed 62 risk factors in its most recent earnings report. Revelation Biosciences reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Loss of Emerging Grown Company Status Q4, 2024
Revelation Biosciences Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $5.22B | 3.32 | -45.04% | 2.83% | 16.81% | -0.27% | |
38 Underperform | $3.30M | ― | -1023.93% | ― | ― | 83.04% | |
32 Underperform | $5.26M | ― | -200.53% | ― | 133.58% | 82.60% | |
28 Underperform | $819.23K | ― | -233.26% | ― | ― | -115.81% | |
| $3.06M | ― | -378.40% | ― | ― | ― | ||
24 Underperform | $2.92M | ― | -178.91% | ― | ― | 82.47% | |
| $3.50M | ― | -89.46% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
REVB
Revelation Biosciences
0.85
-29.87
-97.23%
VIVS
VivoSim Labs
1.80
-10.68
-85.58%
APVO
Aptevo Therapeutics
4.72
-578.40
-99.19%
ENVB
Enveric Biosciences
1.18
-10.40
-89.81%
ENSC
Ensysce Biosciences
2.22
-6.66
-75.00%
SNPX
Synaptogenix
2.52
-2.08
-45.22%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.